Psyence Biomedical Ltd
PBMWW0.018USD
-0.002-10.05%
Close （ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of Psyence Biomedical Ltd Company
Psyence Biomedical Ltd is a Canada-based company, which develops natural psilocybin products for the healing of psychological trauma and its mental health consequences in the context of palliative care. The Company has partnered with iNGENu Pty Ltd (iNGENu) to conduct the Company’s clinical trial in palliative care. iNGENu is an Australia-based, globally focused contract research organization (CRO) with experience working in the psychedelic pharmaceutical drug development and clinical research industry. Its Phase IIb clinical trial, using PEX010, a 25mg naturally derived psilocybin drug candidate product in-licensed by the Company, in the palliative care setting.
Psyence Biomedical Ltd Info
Ticker SymbolPBMWW
Company namePsyence Biomedical Ltd
IPO dateDec 10, 2021
CEODr. Neil Maresky
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
Address121 Richmond Street West Penthouse
CityTORONTO
Stock exchangeNASDAQ Capital Market Consolidated
CountryCanada
Postal codeM5H 2K1
Phone17744604171
Website
Ticker SymbolPBMWW
IPO dateDec 10, 2021
CEODr. Neil Maresky
Company Executives of Psyence Biomedical Ltd
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Jody Aufrichtig
Dr. Jody Aufrichtig
Chairman of the Board, Strategic Business Development Officer
Chairman of the Board, Strategic Business Development Officer
--
--
Dr. Neil Maresky
Dr. Neil Maresky
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Warwick Corden-Lloyd
Mr. Warwick Corden-Lloyd
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Marc Balkin
Mr. Marc Balkin
Independent Director
Independent Director
--
--
Mr. Christopher (Chris) Bull
Mr. Christopher (Chris) Bull
Independent Director
Independent Director
--
--
Dr. Seth Feuerstein
Dr. Seth Feuerstein
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Thu, Jan 1
Updated: Thu, Jan 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q4
53
6.04M
0.00%
-4.14M
2025Q3
55
6.16M
0.00%
-4.02M
2025Q2
54
5.65M
0.00%
-4.58M
2025Q1
56
5.75M
0.00%
-4.55M
2024Q4
58
4.63M
0.00%
-5.55M
2024Q3
65
6.46M
0.00%
-4.73M
2024Q2
67
6.76M
0.00%
-3.47M
2024Q1
67
6.93M
0.00%
-3.84M
2023Q4
66
8.24M
0.00%
-2.37M
2023Q3
64
8.66M
0.00%
-1.45M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Voya Investments, LLC
30.40K
0%
--
--
Oct 31, 2025
TD Securities, Inc.
503.31K
0%
+100.00
+0.02%
Sep 30, 2025
Wolverine Asset Management, LLC
147.10K
0%
+147.10K
--
Sep 30, 2025
Clear Street Group Inc
366.56K
0%
+366.56K
--
Sep 30, 2025
Osaic Holdings, Inc.
100.00K
0%
+100.00K
--
Sep 30, 2025
Susquehanna International Group, LLP
107.91K
0%
-29.53K
-21.49%
Sep 30, 2025
Harraden Circle Investments, LLC
1.15M
0%
--
--
Sep 30, 2025
Polar Asset Management Partners Inc.
733.00K
0%
--
--
Sep 30, 2025
MMCAP Asset Management
600.00K
0%
--
--
Sep 30, 2025
Calamos Advisors LLC
500.00K
0%
--
--
Sep 30, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of Psyence Biomedical Ltd?
The top five shareholders of Psyence Biomedical Ltd are:
Voya Investments, LLC holds 30.40K shares, accounting for 0.00% of the total shares.
TD Securities, Inc. holds 503.31K shares, accounting for 0.00% of the total shares.
Wolverine Asset Management, LLC holds 147.10K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 366.56K shares, accounting for 0.00% of the total shares.
Osaic Holdings, Inc. holds 100.00K shares, accounting for 0.00% of the total shares.
Voya Investments, LLC holds 30.40K shares, accounting for 0.00% of the total shares.
TD Securities, Inc. holds 503.31K shares, accounting for 0.00% of the total shares.
Wolverine Asset Management, LLC holds 147.10K shares, accounting for 0.00% of the total shares.
Clear Street Group Inc holds 366.56K shares, accounting for 0.00% of the total shares.
Osaic Holdings, Inc. holds 100.00K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of Psyence Biomedical Ltd?
The top three shareholder types of Psyence Biomedical Ltd are:
Other
Other
How many institutions hold shares of Psyence Biomedical Ltd (PBMWW)?
As of 2025Q4, 53 institutions hold shares of Psyence Biomedical Ltd, with a combined market value of approximately 6.04M, accounting for --% of the total shares. Compared to 2025Q3, institutional shareholding has increased by --.
What is the biggest source of revenue for Psyence Biomedical Ltd?
In --, the -- business generated the highest revenue for Psyence Biomedical Ltd, amounting to -- and accounting for --% of total revenue.
